Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025) (Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)

Friday, October 27, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Oct. 26, 2017 /PRNewswire/ --

Description The pharmaceutical Industry is a multibillion market

consisting of innovator drugs & generics. The pharmaceutical market consists of a companies involved in the research, development, manufacturing and commercialization of drugs for human & animal use. Download the full report: https://www.reportbuyer.com/product/5045735Geographically,
biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. Biologics are defined as pharmaceutical products obtained from living cells or micro-organisms. These are complex & large molecules consisting of proteins, peptides, nucleic acids, sugars, cellular structures or a combination of these. The biologics drug discovery involves target identification, hit-to-lead stage, lead identification & optimization. Technologies used for the development of biologics include genomics, proteomics, microarrays, cell cultures, phage display technologies and monoclonal antibody technologies among others. The market analysis includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities and challenges) and industry analysis. The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into 'product', 'method', 'manufacture' and 'geographical regions'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market. This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global biologics drug discovery market and assesses the factors governing the same. The answers to the following key questions can be derived from this report: • What are the major market drivers, challenges and opportunities in the global biologics drug discovery market and their case studies? • How the biologics drug discovery market evolve and what did is its scope in the future? • What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2016 and 2025? • How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025? • What are the influencing factors that may affect the market share of the key players? • How will the industry evolve during the forecast period between 2016 and 2025? • What are the key developmental strategies implemented by the key players to stand out in this market? • What will be the growth rate of the outsourced manufacturing segment during the forecast period? • Who are the key outsourced manufacturers of the biologics drug discovery market market? • How the market has been segmented on the basis of phase/method? Which method is highly adopted in the biologics drug discovery process? • Which technologies have been covered in the Target Identification phase? • What will be the value of oncology biologics drug discovery segment by 2025? • Which geographical location will contribute to the highest sales of biologics? • In Europe, which country is dominating the biologics drug discovery market? Also, which country will show the highest growth rate? The key players which have significant contributions to the biologics drug discovery market are Albany Molecular Research Inc., GenScript, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, AbbVie Inc., Amgen Inc., Lilly, Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG, and Biocon Ltd. among others. Executive Summary The introduction of biologic therapies gave a new ray of hope for people suffering from chronic inflammatory diseases. Biologics effected their life not only by reducing dependency on health and welfare systems but also by improving their physical function to live independently. The entry of biosimilars makes these effective therapies more affordable, though the concern of after effects still exists. The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into 'product', 'method', 'manufacture' and 'geographical regions'. The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future. Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs. The global biologics drug discovery market can be segmented based on the basis of phase of discovery into target identification, hit generation, lead identification & lead optimization. The major contributor towards the market in 2016 was the lead optimization phase. Based on the manufacture type, the market is segmented into in-house & outsourced. The in-house market for the global biologics drug discovery was estimated to be $6.5 billion in 2016. The CAGR was highest for the out-sourced manufacturing. Moreover, based on the product type, monoclonal antibody is anticipated to be the major contributor to the market. The market for the drug discovery of monoclonal antibody is expected to reach $10.7 billion by 2025. The next contributing segment is recombinant proteins. Geographically, the largest contributor to the growth of the global biologics drug discovery market was found to be North America due to the presence of pharmaceutical companies involved in R&D of biologics. This was followed by Europe. The fastest growing region was Asia-pacific due to the increasing presence of Contract Research Organisations (CRO). Biologics are expected to contribute 50% to the sales of the top 100 products during the forecast period. This will lead to increased investment in the global biologics drug discovery market in future. For instance, in 2016, among the most valued R&D projects were Roche' Ocrelizumab & Sanofi's Dupilumab. And in 2017, Ocrevus (Ocrelizumab) & Dupixient (dupilumab) were among the top 2 product launches so far. The biologics market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy and bio-betters presents opportunities for the further growth of the biologics drug discovery market. The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. Some of the key players are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb GmbH, Novo Nordisk, Merck KGaA and Allergan, Plc. Countries Covered North America Europe Asia-Pacific RoWDownload the full report: https://www.reportbuyer.com/product/5045735 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/global-biologics-drug-discovery-market-analysis-and-forecast-2017-2025-focus-on-methodphase-product-type-manufacturer-type-and-competitive-landscape-300544383.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store